Demetris Papamichael

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Eric Van Cutsem, Andrés Cervantes, René Adam et al. · Annals of Oncology · 2016 · 3.4K citations · Full text

Medicine, Oncology, Surgery +13

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study

Thierry André, Armand de Gramont, Déwi Vernerey et al. · Journal of Clinical Oncology · 2015 · 675 citations

Medicine, Molecular Genetics, Oncology +17

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

Rabab Gaafar, Veerle Surmont, Giorgio V. Scagliotti et al. · European Journal of Cancer · 2011 · 119 citations

Medicine, Oncology, Pharmacology +5

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

George Pentheroudakis, Vassiliki Kotoula, Wendy De Roock et al. · BMC Cancer · 2013 · 111 citations · Full text

Medicine, Oncology, Pharmacology +17